WHF partners with AZ to reduce burden of CV disease
New initiatives will raise public awareness of the burden of heart failure to boost prevention, diagnosis and treatment
Read More
Tag: CV
CV patients finding it harder to get treatment during pandemic
The BHF is calling on the government to address the issue or the backlog will continue to grow putting patients at risk of getting sicker
Read More
AZ’ Farxiga shows CV benefit in diabetes patients
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
Read More
EU approves Repatha for reduction of CV risk
The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).
Read More
Sanofi, Regeneron to cut price of Praluent
Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
Read More
AZ’ Tudorza hits study goals in COPD patients with CV risk factors
AstraZeneca says top-line results from a post-marketing study show that Tudorza Pressair is effective in reducing chronic obstructive pulmonary disease (COPD) exacerbations in patients with cardiovascular issues.
Read More
Extended use of AZ’ Brilinta cuts CV death risk 29%
Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
